INS and Hypoglycemia: Treatment with SGLT2 inhibitors added to adjunctive therapy with basal-bolus regimen insulin have demonstrated reduced HbA1c and lower glucose variability with increased time in optimal glucose range as well as additional benefits in terms of reductions in weight and insulin dose without increasing the incidence of hypoglycemia.